3.37 0.00 (0.00%)
After hours: 4:21PM EDT
|Bid||3.33 x 2900|
|Ask||3.75 x 1000|
|Day's Range||3.33 - 3.46|
|52 Week Range||3.00 - 4.60|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.25|
Nymox Pharmaceutical Corporation (NYMX) announced today that following the recently announced increased manufacturing capabilities, the Company has formally decided to expand its European marketing plans for Fexapotide Triflutate (FT) to all countries in the European Community. Earlier this month Nymox announced that it had successfully accomplished important milestones relating to manufacturing scale-up for FT. Consequently, the Company is now in the enhanced position to have sufficient manufacturing capacities in place to be able to realistically meet anticipated physician demand for FT upon approval.
HASBROUCK HEIGHTS, N.J., June 07, 2018-- Nymox Pharmaceutical Corporation is pleased to report that manufacturing scale-up milestones have been reached for the Company's lead compound Fexapotide Triflutate. ...
Nymox Pharmaceutical Corporation (NYMX) is pleased to report on a successful symposium discussing Nymox’s lead product candidate Fexapotide Triflutate (FT) as a novel therapeutic option in BPH at the Annual Meeting of the American Urological Association in San Francisco, this past weekend. Dr. Ronald Tutrone of Chesapeake Urology Research Associates, Baltimore MD, and a principal investigator in the trials, chaired the meeting and presented clinically relevant therapeutic highlights from the trials.
On a per-share basis, the St.-Laurent, Quebec-based company said it had a loss of 5 cents. The biopharmaceutical company posted revenue of $152,000 in the period. The company's shares closed at $3.92. ...
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that an informative interview and presentation was released on Grand Rounds in Urology, a highly respected and authoritative urologic professional community, and host of international conferences and symposia that bring together the top thought leaders in the treatment of urologic disease, with meetings that focus on current best treatment practices as well as future trends and directions. Grand Rounds in Urology is hosted and edited by Dr. E. David Crawford of the University of Colorado. Dr. Crawford is an international expert in urological research who is a Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado, Denver CO. The presentation was given by Dr. Ronald Tutrone Jr., MD FACS of Chesapeake Urology Research Associates, Towson, MD.
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that it has initiated the process of relocating the Company Headquarters from Nassau, Bahamas to Zug in Switzerland. Following its recent successful financing the Company is now preparing for scale-up and commercialization for Fexapotide Triflutate as a completely new treatment option for the millions of men currently suffering from prostate problems associated with aging and prostate enlargement (BPH). The Company will be relocating to Zug in Switzerland, one of the most important biotech and pharma hubs in Europe, where it will have direct access to an excellent infrastructure supporting its anticipated growth and an abundant pool of skillful, experienced commercial and pharma sales professionals.
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that there will be a Symposium on the Company's lead drug Fexapotide held at the Annual Meeting of the American Urological Association on May 20 in San Francisco. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.
In this article, I’m going to take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
Leading Nymox Pharmaceutical Corporation (NASDAQ:NYMX) as the CEO, Paul Averback took the company to a valuation of US$236.27M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
For Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. NYMX is exposedRead More...
Today I will take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past fewRead More...
Categories: Yahoo FinanceGet free summary analysis Nymox Pharmaceutical Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Nymox Pharmaceutical Corp. – Abbott Laboratories, Eli Lilly and Company, Quest Diagnostics Incorporated, Pfizer Inc., Johnson & Johnson and Sophiris Bio Inc. (ABT-US, LLY-US, DGX-US, PFE-US, JNJ-US and ... Read more (Read more...)
If you are a shareholder in Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...